HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use XELJANZ/XELJANZ XR/XELJANZ Oral Solution safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR/XELJANZ Oral Solution.
XELJANZ® (tofacitinib) tablets, for oral use
XELJANZ® XR (tofacitinib) extended-release tablets, for oral use
XELJANZ® (tofacitinib) Oral Solution
Initial U.S. Approval: 2012
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
XELJANZ / XELJANZ XR Highlights (tofacitinib)
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at